

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

CHANGE OF EMPLOYEE REPRESENTATIVE DIRECTORS

The Board of the Company announces that (i) Mr. Wang Jianyi has been elected as the employee representative Director of the seventh session of the Board; and (ii) Mr. Zhang Ping ceased to serve as the employee representative Director of the sixth session of the Board upon expiry of his term of appointment, in both cases with effect from the conclusion of the 2025 AGM.

ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR OF THE SEVENTH SESSION OF THE BOARD

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that the Company recently held the employee representative meeting and elected Mr. Wang Jianyi (“**Mr. Wang**”) as the employee representative Director of the seventh session of the Board, which took effect from the conclusion of the 2025 annual general meeting of the Company (the “**2025 AGM**”) with the same term as the seventh session of the Board of the Company. The biographical details of Mr. Wang are set out as follows:

Mr. Wang Jianyi (王建一), aged 43, is a citizen of China and holds a bachelor’s degree from Xihua University. He joined the Company in 2008 and served as the Manager of the Procurement/Inventory Control Department of Shenzhen Techdow Pharmaceutical Co., Ltd. From 2010 onward, he successively held positions including Manager of the Human Resources Department of the Company. He is currently the Director of Organization and Human Resources of the Company.

As at the date of this announcement, Mr. Wang has no connected relationship with any shareholder holding 5% or more of the Company’s shares, the de facto controllers, or any other director or member of senior management of the Company.

As at the date of this announcement, the spouse of Mr. Wang holds an aggregate of 2,300 A shares of the Company. Accordingly, Mr. Wang is deemed to have an interest in such A shares held by his spouse. In addition, Mr. Wang participates in the Share Incentive Scheme II implemented in November 2016 and had a 1.42% interest in the 15,118,025 A shares held by the asset manager for the benefit of the scheme participants, representing an aggregate indirect holding of approximately 0.01% of the Company's total share capital.

Save as disclosed above, Mr. Wang did not hold any other positions of the Company or its subsidiaries, nor serve as a director of any public company with securities listed on any securities market in Hong Kong or overseas in the past three years, nor has other major appointments and professional qualifications, and does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company, and does not have and is not deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Wang's service contract provides for a term of three years. His emoluments comprise an annual Director's fee for acting as a member of the Board (which will be proposed by the Board for approval by the shareholders at the subsequent year's annual general meeting). His total emoluments received during the year ended December 31, 2025 amounted to approximately RMB1,701,000. His emoluments are determined by reference to his duties and responsibilities with the Company, the Company's performance and profitability, the Company's remuneration policy and the market benchmark.

As at the date of this announcement, save as disclosed above, there is no other information in relation to the election of Mr. Wang as an employee representative Director required to be disclosed under Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited or that need to be brought to the attention of the H share shareholders of the Company.

The Board would like to welcome Mr. Wang for joining as a member of the Board.

EXPIRY OF TERM OF APPOINTMENT OF EMPLOYEE REPRESENTATIVE DIRECTOR OF THE SIXTH SESSION OF THE BOARD

The Board announces that Mr. Zhang Ping (“**Mr. Zhang**”) ceased to serve as the employee representative Director of the sixth session of the Board upon expiry of his term of appointment at the conclusion of the 2025 AGM.

Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter in relation to the expiry of his term of appointment that needs to be brought to the attention of the H share shareholders of the Company.

The Board would like to express its gratitude to Mr. Zhang for his valuable contributions to the Company during his tenure of office.

An updated List of Directors and Their Role and Function including the composition of each of the committees of the Board is also made available on the websites of The Stock Exchange of Hong Kong Limited and the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
May 22, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Wang Jianyi; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.